Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group Ltd. announced the conversion of a portion of its Tranche A Bonds, valued at US$10,000,000, at a conversion price of HK$3.672 per share. This move is part of the company’s ongoing financial management and compliance with regulatory requirements, aiming to maintain transparency and equal information dissemination among investors.
The most recent analyst rating on (HK:2186) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, focusing on the development, production, and sale of innovative medications. The company is listed on the Hong Kong Stock Exchange and is involved in the issuance of convertible bonds as part of its financial strategies.
Average Trading Volume: 104,058,469
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.89B
For a thorough assessment of 2186 stock, go to TipRanks’ Stock Analysis page.